BioCryst Pharmaceuticals Inc (BCRX) stock
Close on Nov 17, 2026Market cap $1.92BP/E –Yield –
Earnings
BioCryst Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of BioCryst Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026before the open | $180.30M | +13.1% | $0.14 | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026before the open | $218.30M | +33.6% | $0.30 | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 6, 2026before the open | – | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026before the open | $406.56M | +209.2% | $1.12 | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 3, 2025before the open | $159.40M | +36.1% | $0.06 | $0.16 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 4, 2025before the open | $163.40M | +49.5% | $0.02 | $0.15 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 5, 2025before the open | $145.50M | +56.8% | $0.00 | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 24, 2025before the open | $131.50M | +40.8% | -$0.13 | -$0.13 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 4, 2024before the open | $117.10M | +35.1% | -$0.07 | -$0.07 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 5, 2024before the open | $109.30M | +32.5% | -$0.06 | -$0.06 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 6, 2024before the open | $92.80M | +34.9% | -$0.17 | -$0.17 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 26, 2024before the open | $93.40M | +17.5% | -$0.31 | -$0.28 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023before the open | $86.70M | +14.4% | -$0.19 | -$0.19 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023before the open | $82.50M | +26.0% | -$0.40 | -$0.24 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 3, 2023before the open | $68.80M | +37.9% | -$0.28 | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 21, 2023before the open | $79.50M | +68.4% | -$0.38 | -$0.38 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 1, 2022before the open | $75.80M | +84.9% | -$0.23 | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022before the open | $65.50M | – | -$0.32 | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022before the open | $49.90M | – | -$0.40 | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 23, 2022before the open | $47.20M | – | -$0.10 | -$0.40 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 3, 2021before the open | $41.00M | – | -$0.33 | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 25, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
BioCryst Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| ORLADEYO revenue | FY2026 | $625.00M – $645.00M | $625.00M – $645.00M | Lowered | Aug 5, 2026 |
| total revenue outlook | FY2026 | $715.00M – $730.00M | $625.00M – $645.00M | Raised | Nov 4, 2026 |
| global net ORLADEYO revenue | FY2026 | $625.00M – $645.00M | – | New | Nov 4, 2026 |
| Non-GAAP operating expense including Astria acquisitionnon-GAAP | FY2026 | $450.00M – $470.00M | – | Raised | Jan 12, 2026 |
| non-GAAP operating expensesnon-GAAP | FY2026 | $415.00M – $425.00M | $450.00M – $470.00M | Lowered | Nov 4, 2026 |
| non-GAAP operating expensesnon-GAAP | FY2026 | $420.00M – $440.00M | $450.00M – $470.00M | Lowered | Aug 5, 2026 |
| non-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costsnon-GAAP | FY2026 | $380.00M – $390.00M | – | New | Jan 12, 2026 |
Guidance history
Every forecast BioCryst Pharmaceuticals put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 4, 2026 | global net ORLADEYO revenue | FY2026 | $625.00M – $645.00M | New |
| Nov 4, 2026 | non-GAAP operating expenses | FY2026 | $415.00M – $425.00M | Lowered |
| Nov 4, 2026 | total revenue outlook | FY2026 | $715.00M – $730.00M | Raised |
| Aug 5, 2026 | non-GAAP operating expenses | FY2026 | $420.00M – $440.00M | Lowered |
| Aug 5, 2026 | ORLADEYO revenue | FY2026 | $625.00M – $645.00M | Lowered |
| Aug 5, 2026 | total revenue | FY2026 | $690.00M – $715.00M | Raised |
| May 6, 2026 | non-GAAP operating expenses | FY2026 | $450.00M – $470.00M | Reaffirmed |
| May 6, 2026 | ORLADEYO revenue | FY2026 | $625.00M – $645.00M | Lowered |
| May 6, 2026 | total revenue | FY2026 | $635.00M – $660.00M | Raised |
| Feb 26, 2026 | non-GAAP operating expenses | FY2026 | $450.00M – $470.00M | New |
| Feb 26, 2026 | global net ORLADEYO revenue | FY2026 | $625.00M – $645.00M | New |
| Feb 26, 2026 | total revenue, including RAPIVAB® (peramivir injection) | FY2026 | $635.00M – $660.00M | Raised |
| Jan 12, 2026 | non-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costs | FY2026 | $380.00M – $390.00M | New |
| Jan 12, 2026 | Non-GAAP operating expense including Astria acquisition | FY2026 | $450.00M – $470.00M | Raised |
| Jan 12, 2026 | ORLADEYO revenue | FY2026 | $625.00M – $645.00M | New |
| Jan 12, 2026 | total revenue, including RAPIVAB® (peramivir injection) | FY2026 | $635.00M – $660.00M | Raised |
| Nov 3, 2025 | non-GAAP operating expenses | FY2025 | $430.00M – $440.00M | Lowered |
| Nov 3, 2025 | global net ORLADEYO revenue | FY2025 | $590.00M – $600.00M | Raised |
| Aug 4, 2025 | non-GAAP operating expenses | FY2025 | $440.00M – $450.00M | Reaffirmed |
| Aug 4, 2025 | global net ORLADEYO revenue | FY2025 | $580.00M – $600.00M | Reaffirmed |
| May 5, 2025 | operating expenses | FY2025 | $440.00M – $450.00M | Raised |
| May 5, 2025 | global net ORLADEYO revenue | FY2025 | $580.00M – $600.00M | Raised |
| Feb 24, 2025 | global net ORLADEYO revenue | FY2025 | $535.00M – $550.00M | New |
| Feb 24, 2025 | non-GAAP operating expense | FY2025 | $425.00M – $435.00M | Reaffirmed |
| Feb 24, 2025 | total revenue | FY2025 | $560.00M – $575.00M | Raised |
| Jan 10, 2025 | operating expenses | FY2025 | $485.00M – $495.00M | New |
| Jan 10, 2025 | operating expenses not including stock-based compensation | FY2025 | $425.00M – $435.00M | New |
| Jan 10, 2025 | ORLADEYO net revenue | FY2025 | $515.00M – $535.00M | New |
| Jan 10, 2025 | Total revenue | FY2025 | $540.00M – $560.00M | Raised |
| Nov 4, 2024 | operating expenses | FY2024 | $380.00M – $390.00M | Raised |
| Nov 4, 2024 | global net ORLADEYO revenue | FY2024 | $430.00M – $435.00M | Raised |
| Nov 4, 2024 | total revenue | FY2024 | $443.00M – $448.00M | Raised |
| Aug 5, 2024 | operating expenses | FY2024 | $365.00M – $375.00M | Reaffirmed |
| Aug 5, 2024 | global net ORLADEYO revenue | FY2024 | $420.00M – $435.00M | Raised |
| May 6, 2024 | operating expenses | FY2024 | $365.00M – $375.00M | Reaffirmed |
| May 6, 2024 | global net ORLADEYO revenue | FY2024 | $390.00M – $400.00M | Raised |
| Feb 26, 2024 | operating expenses | FY2024 | $365.00M – $375.00M | New |
| Feb 26, 2024 | global net ORLADEYO revenue | FY2024 | $380.00M – $400.00M | New |
| Nov 2, 2023 | operating expenses, not including non-cash stock compensation | FY2023 | $365.00M – $375.00M | Lowered |
| Nov 2, 2023 | global net ORLADEYO revenue | FY2023 | $320.00M | Reaffirmed |
| Aug 3, 2023 | Operating expenses | FY2023 | $375.00M | Reaffirmed |
| Aug 3, 2023 | global net ORLADEYO revenue | FY2023 | $320.00M | Reaffirmed |
| May 3, 2023 | Operating expenses, not including non-cash stock compensation | FY2023 | $375.00M | Reaffirmed |
| May 3, 2023 | global net ORLADEYO revenue | FY2023 | $320.00M | Reaffirmed |
| Feb 21, 2023 | Operating expenses, not including non-cash stock compensation | FY2023 | $375.00M | New |
| Feb 21, 2023 | global net ORLADEYO revenue | FY2023 | $320.00M | New |
| Nov 1, 2022 | operating expenses | FY2022 | $365.00M – $370.00M | Lowered |
| Nov 1, 2022 | net ORLADEYO revenue | FY2022 | $255.00M | Lowered |
| Aug 4, 2022 | operating expenses, not including non-cash stock compensation | FY2022 | $390.00M – $400.00M | Lowered |
| Aug 4, 2022 | net ORLADEYO revenue | FY2022 | $255.00M – $265.00M | Raised |
| May 5, 2022 | net ORLADEYO revenue | FY2022 | $250.00M | Reaffirmed |
| Feb 23, 2022 | Operating expenses | FY2022 | $440.00M – $480.00M | New |
| Feb 23, 2022 | net ORLADEYO revenue | FY2022 | $250.00M | New |
| Nov 3, 2021 | net ORLADEYO revenue | FY2021 | $115.00M – $120.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases BioCryst Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Update
- Results
- BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary AngioedemaUpdate
- Update
- Update
- Results
- News
- News
- Results
- Results
- Results
See a number that looks wrong?